Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2025-06-01 Share Issue/Capital Cha…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Notification regarding unquoted securities - MVP 6 pages 19.2KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of performance rights under an employee incentive scheme. It includes specifics such as the number of securities issued, dates, and mentions key management personnel receiving securities. The document is a formal notification of a securities issue, specifically unquoted equity securities, which aligns with announcements about share issues or capital changes. There is no indication of it being a full financial report, audit, or management discussion. The content fits the category of announcements regarding new share issues or capital changes rather than a report or regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail support a confident classification.
2025-06-01 English
Director Appointment and Resignation 2 pages 227.5KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 30 May 2025 regarding the resignation and appointment of a director on the company's board. It details the departure of Richard Betts and the appointment of Paul Townsend, including their roles and backgrounds. There is no financial data, earnings information, or report attached or referenced. The content focuses solely on changes in the company's board of directors. According to the filing definitions, announcements about changes in the company's board or senior management fall under 'Board/Management Information' (Code: MANG). The document length is 4133 characters, which is consistent with a typical announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2025-05-29 English
Initial Director's Interest Notice 2 pages 251.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, with no financial data or report content. This is a notification of personal share transactions or interests by a company director, fitting the definition of Director's Dealing filings. The document length is short and focused solely on director interests, confirming it is not a financial report or other type of filing.
2025-05-29 English
Appendix 4C and Quarterly Activity Report - 31 March 2025 8 pages 375.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as an ASX Announcement and contains a Quarterly Activity Report and Appendix 4C for the third quarter of fiscal year 2025 (Q3 FY25). It includes detailed unaudited financial information such as cash flow statements, revenue figures, operating cash flow, and strategic updates for the quarter ended 31 March 2025. The presence of Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report but includes the actual financial data and commentary. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2025
2025-04-28 English
Initial Director's Interest Notice - M. Fladrich 2 pages 251.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, indicating it is a report of personal share transactions or interests by a company director. The content is consistent with a Director's Dealing report, which involves disclosure of directors' shareholdings or interests. The document length is short and focused solely on director interests, not financial results or other report types.
2025-03-31 English
Appointment of Director - Mark Fladrich 2 pages 226.6KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 21 March 2025 regarding the appointment of a new director, Mark Fladrich, to the Board of Medical Developments International Limited. The content focuses exclusively on the new board member's background, qualifications, and the company's statement welcoming him. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, and no other types of filings. The document is a clear announcement of a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 4026 characters, which is consistent with a typical announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2025-03-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.